If you’ve ever wondered whether there’s something more you can do to help build focus abilities beyond traditional approaches, you’re asking exactly the right question. That instinct—the sense that the brain can be trained and strengthened—now has significant new backing from the FDA. A prescription digital therapeutic has just received clearance for adults developing attention regulation skills, and the research behind it points to something parents and educators have long believed: focused practice can change the brain.
FDA Clears Cognitive Training App for Adults Building Focus
The U.S. Food and Drug Administration has granted 510(k) clearance to LumosityRx, a prescription digital therapeutic designed to improve attention function in adults ages 22 to 55 who are developing attention regulation skills. The clearance, announced in December 2025 by Lumos Labs (the company behind the popular Lumosity brain-training platform), marks a significant milestone in validating cognitive training approaches for building focus capabilities.
The app delivers clinically validated versions of 13 cognitive training games targeting the mental processes that contribute to attention function. Users engage with the app for approximately 15 minutes daily as part of a broader therapeutic program that may include clinician-directed therapy, other support approaches, or educational programs.
The FDA just cleared a brain-training app for building focus skills—with 97% adherence and 1 in 3 users rated "much improved." Attention is trainable.
Large Clinical Trial Demonstrates Measurable Attention Gains
The FDA clearance was supported by the GAMES study, a randomized, double-blind, sham-controlled trial involving 560 participants. Over nine weeks, participants using LumosityRx showed statistically significant improvements on an objective measure of sustained and selective attention—the TOVA (Test of Variables of Attention) with a p-value of 0.0149. This finding aligns with what research on focus development has consistently shown: attention is a trainable skill that strengthens through systematic practice.
Beyond test scores, 44.2% of participants met the study’s responder threshold, and approximately one in three were rated “much improved” or better by clinical investigators. Participants also reported meaningful quality-of-life improvements, with an average 8.7-point increase on the Adult ADHD Quality of Life scale.
Strong Adherence and Minimal Side Effects Signal Practical Viability
One of the study’s most encouraging findings was the exceptionally high adherence rate: 97% of prescribed use was completed over the nine-week treatment period. This matters because any approach to building focus skills only works if people actually use it consistently. The commitment participants showed suggests that the app’s game-based format may help sustain the dopamine engagement needed for lasting behavior change.
Safety data was equally reassuring. No serious adverse events were reported during the trial, and treatment-related adverse events occurred in less than 1% of participants. The reported effects were described as mild. This stands in contrast to some traditional approaches and offers families another option in their toolkit for building focus capabilities.
Key takeaways
- FDA clears first brain-training therapeutic for focus: LumosityRx becomes the first prescription digital app cleared for adults ages 22-55 developing attention regulation skills.
- Large trial shows measurable attention improvement: A 560-participant study found statistically significant gains in sustained attention, with 44% meeting responder thresholds and one in three rated "much improved."
- High adherence suggests practical viability: Participants completed 97% of prescribed use over nine weeks with less than 1% experiencing mild side effects.
A Validation of Brain-Training for Focus Development
For parents and educators who have long believed that attention can be developed through the right kind of practice, this FDA clearance represents external validation of a core principle: the brain changes in response to targeted training. While LumosityRx is currently designed for adults, the underlying neuroscience applies across ages. Stanford research has demonstrated that attention and executive function skills are highly trainable throughout childhood, and four weeks of sustained attention practice can create measurable brain changes that transfer to academic performance.
Lumos Labs is now working toward a national product launch to ensure broad access. For families supporting children who are building focus skills, this development reinforces the value of consistent, targeted cognitive training—whether through clinical tools, focus-building programs, or daily practice routines that strengthen the attention “muscle” over time.
Every child—and every adult—deserves to know that their brain can change, grow, and build new capabilities. This is what neuroplasticity research has shown for decades, and it’s what the FDA has now validated for attention skills: consistent, targeted practice creates measurable brain change. The real frustration isn’t that people lack focus abilities—it’s that too many approaches manage symptoms rather than build skills. If you’re ready to move beyond labels and toward genuine capability-building, the Learning Success All Access Program offers a free trial that includes a personalized Action Plan—and you keep that plan even if you decide it’s not the right fit.
See what All Access gives your child
Explore Focus Foundations
Is your child struggling in school?
Get your free personalized learning roadmap
You describe what you see at home. We turn it into a plan you start this week.
- Answer 5 short questionnaires about what you already notice, 30–45 minutes at your own kitchen table
- Your child sits no test and gets no score: nothing to schedule, nothing for them to dread
- You do the answering, the AI does the writing, and a person reviews it before it reaches you
- Access all 40+ courses instantly: reading, math, focus, processing and more, with new ones added regularly
Why we use AI, plainly: it writes from a knowledge base our team maintains and audits. We work through it line by line and pull anything the evidence stops supporting. The roadmap you get on Tuesday reflects what we corrected on Monday, and a human still reads it before you do.
Your school district must evaluate your child free of charge if you ask in writing, whatever your income and whatever the outcome (US, 34 CFR 300.111 and 300.301(b)). That route takes time and answers a different question than you do. This one starts today, from what you already know.
Your answers stay yours. We do not sell your personal information, and we do not hand identifiable assessment data to outside AI companies to train their models.
A screener is a starting point, not a diagnosis. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a vision, hearing or medical cause, pursue a professional evaluation too. That is the only route to those supports.
References
- ADDitude Magazine - Prescription Digital Therapeutics for ADHD
- Business Wire - Lumosity Announces FDA Clearance of LumosityRx
